Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain
Cattaneo, Carlo (Bresso, MI Italy)
Kulisevsky, Jaime (Institut d'Investigació Biomèdica Sant Pau)
Tubazio, Viviana (Bresso, MI Italy)
Castellani, Paola (Bresso, MI Italy)
Universitat Autònoma de Barcelona

Fecha:	2018
Resumen:	Chronic pain is an important yet overlooked non-motor symptom of Parkinson's disease (PD), caused by an imbalance of the dopaminergic and glutamatergic systems. Safinamide has a multimodal mechanism of action, dopaminergic (reversible MAO-B inhibition) and non-dopaminergic (modulation of the abnormal glutamate release), that might be beneficial for both motor and non-motor symptoms. To investigate the long-term (2-year) efficacy of safinamide on PD chronic pain and to confirm the positive effects observed after 6 months of treatment. This is a post hoc analysis of the data from the 2-year study 018, focused on the reduction of concomitant pain treatments and on the scores of pain-related items of the Parkinson's disease quality of life questionnaire (PDQ-39). Safinamide, compared with placebo, significantly improved the PDQ-39 items 37 ("painful cramps or spasm," p = 0. 0074) and 39 ("unpleasantly hot or cold," p = 0. 0209) and significantly reduced the number of concomitant pain treatments by 26. 2% (p = 0. 005). A significantly greater proportion of patients in the safinamide group was not using pain drugs after 2 years of treatment (p = 0. 0478). The positive effects of safinamide on PD chronic pain were maintained in the long term. Further investigations are desirable to confirm their clinical relevance. Zambon SpA.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Glutamate ; Neurology ; Pain ; Parkinson's disease ; Safinamide
Publicado en:	Advances in Therapy, Vol. 35 (march 2018) , p. 515-522, ISSN 1865-8652

DOI: 10.1007/s12325-018-0687-z
PMID: 29542008

8 p, 594.5 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados